CRESSKILL, N.J., Nov. 12, 2008 (GLOBE NEWSWIRE) -- Vascular Therapies LLC, a combination product company, recently announced encouraging safety and efficacy data from the company’s First-in-Man study wherein the COLL-R membrane (a sirolimus eluting biodegradable collagen membrane) was implanted at the PTFE graft venous anastomotic site.
